Sally Ditzler
Overview
Explore the profile of Sally Ditzler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
357
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brabetz S, Leary S, Grobner S, Nakamoto M, Seker-Cin H, Girard E, et al.
Nat Med
. 2018 Oct;
24(11):1752-1761.
PMID: 30349086
Brain tumors are the leading cause of cancer-related death in children. Genomic studies have provided insights into molecular subgroups and oncogenic drivers of pediatric brain tumors that may lead to...
2.
Girard E, Ditzler S, Lee D, Richards A, Yagle K, Park J, et al.
Neuro Oncol
. 2014 Aug;
17(1):107-15.
PMID: 25140037
Background: There is an unmet need in the treatment of pediatric brain tumors for chemotherapy that is efficacious, avoids damage to the developing brain, and crosses the blood-brain barrier. These...
3.
Dey J, Ditzler S, Knoblaugh S, Hatton B, Schelter J, Cleary M, et al.
Mol Cell Biol
. 2012 Aug;
32(20):4104-15.
PMID: 22869526
Deregulated developmental processes in the cerebellum cause medulloblastoma, the most common pediatric brain malignancy. About 25 to 30% of cases are caused by mutations increasing the activity of the Sonic...
4.
Lee M, Hatton B, Villavicencio E, Khanna P, Friedman S, Ditzler S, et al.
Proc Natl Acad Sci U S A
. 2012 May;
109(20):7859-64.
PMID: 22550175
The Sonic Hedgehog (Shh) pathway drives a subset of medulloblastomas, a malignant neuroectodermal brain cancer, and other cancers. Small-molecule Shh pathway inhibitors have induced tumor regression in mice and patients...
5.
Lee M, Veiseh O, Bhattarai N, Sun C, Hansen S, Ditzler S, et al.
PLoS One
. 2010 Mar;
5(3):e9536.
PMID: 20209054
Background: Recent advances in nanotechnology have led to the development of biocompatible nanoparticles for in vivo molecular imaging and targeted therapy. Many nanoparticles have undesirable tissue distribution or unacceptably low...
6.
Hatton B, Villavicencio E, Tsuchiya K, Pritchard J, Ditzler S, Pullar B, et al.
Cancer Res
. 2008 Mar;
68(6):1768-76.
PMID: 18339857
Toward the goal of generating a mouse medulloblastoma model with increased tumor incidence, we developed a homozygous version of our ND2:SmoA1 model. Medulloblastomas form in 94% of homozygous Smo/Smo mice...